US Hits Indian Torsion Springs with Anti-Dumping Duties
Published Date: 2/20/2026
Notice
Summary
The U.S. found that imports of overhead door counterbalance torsion springs from India are hurting American companies because they’re being sold too cheaply and getting unfair government help. As a result, special duties will be applied to these imports to protect U.S. businesses. This change affects importers and manufacturers starting soon, aiming to level the playing field and support local jobs.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Special duties on Indian spring imports
Special antidumping and countervailing duties will be applied to imports of overhead door counterbalance torsion springs from India because Commerce found those imports were sold at less than fair value and subsidized. The Commission completed and filed its determinations on February 17, 2026, which triggers trade-remedy actions affecting importers of these parts.
Findings aim to protect U.S. manufacturers
The Commission found that U.S. producers of overhead door counterbalance torsion springs are materially injured by imports from India. The determinations are intended to level the playing field and support local U.S. manufacturers and jobs.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16811, Certain Ink Cartridges and Components Thereof II; Notice of a Commission Determination Finding a Violation Under Section 337; Issuance of a General Exclusion Order and Cease and Desist Orders; Termination of the Investigation
Notice is hereby given that the U.S. International Trade Commission has determined to find a violation under section 337 of the Tariff Act of 1930, as amended, and to issue a general exclusion order ("GEO") prohibiting the importation of products that infringe claims 1 and 7 of each of the following patents: U.S. Patent Nos. 8,764,172 ("the '172 patent"); 9,370,934 ("the '934 patent"); 11,535,038 ("the '038 patent"); 12,240,248 ("the '248 patent"); and 12,240,249 ("the '249 patent"); and cease and desist orders ("CDOs") against respondents Mountain Peak, Inc. and Straightouttaink, LP. The investigation is terminated.
2026-16816, Hand Trucks and Certain Parts Thereof From China; Determination
2026-16581, Carbazole Violet Pigment 23 From China and India; Termination of Five-Year Reviews
The Commission instituted the subject five-year reviews on May 1, 2026 to determine whether revocation of the countervailing duty order on carbazole violet pigment 23 from India and the antidumping duty orders on carbazole violet pigment 23 from China and India would be likely to lead to continuation or recurrence of material injury. On August 7, 2026, the Department of Commerce published notice in the Federal Register that it was revoking the orders applicable August 7, 2026, because no domestic interested party filed a timely notice of intent to participate. Accordingly, the subject reviews are terminated.
2026-16667, Certain Mobile Electronic Devices; Notice of Institution of Investigation
Notice is hereby given that a complaint was filed with the U.S. International Trade Commission on July 10, 2026, under section 337 of the Tariff Act of 1930, as amended, on behalf of Maxell, Ltd. of Kyoto, Japan. An amended complaint was filed on July 24, 2026. The amended complaint alleges violations of section 337 based upon the importation into the United States, the sale for importation, and the sale within the United States after importation of certain mobile electronic devices by reason of the infringement of certain claims of U.S. Patent No. 10,812,646 ("the '646 patent"); U.S. Patent No. 12,513,408 ("the '408 patent"); U.S. Patent No. 12,061,760 ("the '760 patent"); U.S. Patent No. 12,418,692 ("the '692 patent"); U.S. Patent No. 12,185,211 ("the '211 patent"); and U.S. Patent No. 12,647,935 ("the '935 patent"). The amended complaint further alleges that an industry in the United States exists as required by the applicable Federal Statute. The amended complainant requests that the Commission institute an investigation and, after the investigation, issue a limited exclusion order and cease and desist orders.
2026-16469, Choline Salts From China; Determinations
The U.S. International Trade Commission found that imports of choline salts from China might be hurting American businesses by being sold unfairly cheap and getting government help. This means a deeper investigation is starting soon, which could lead to new rules or tariffs to protect U.S. companies. If you’re involved in this industry, keep an eye out for updates and possible changes that could affect prices and trade.
2026-16302, Large Vertical Shaft Engines From China; Determinations
Previous / Next Documents
Previous: 2026-03324, Certain Composite Intermediate Bulk Containers; Notice of Commission Determination on Remedy, the Public Interest, and Bonding for a Defaulting Respondent; Termination of Investigation
The U.S. International Trade Commission has decided to block certain bulk containers made by Hebei Shijiheng Plastics from entering the U.S. and requires a full bond from them because they didn’t respond properly. This action protects companies like Schütz Container Systems and Protechna, who own the patents, without hurting the public. The investigation is now officially over, so these rules kick in right away.
Next: 2026-03326, Agency Information Collection Activities; Proposed Collection; Comment Request; Current Good Manufacturing Practice (CGMP): Manufacturing, Processing, Packing, and Holding of Drugs; GMP for Finished Pharmaceuticals (Including Active Pharmaceutical Ingredients) and the Advanced Manufacturing Technologies Designation Program
The FDA wants your thoughts on how they collect info about making and handling medicines safely, including new tech in drug manufacturing. This affects drug makers and anyone involved in producing medicines, with a comment deadline of April 21, 2026. No big costs or changes yet—just a chance to help shape future rules!